fashion -WSS

fashion

author：Wikipedia 2025-10-02 07:01:34 - browse：68746

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Personalized medicine goes far beyond genetics

WSS

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Medical experts exlpore how to eliminate bias in clinical algorithms

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

How to ethically and practically extend health care to all

leisure time

fashion

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare slashes safety net hospital payments by nearly $1 billion

Bright Health sells Medicare Advantage business to Molina

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

United colonoscopy coverage change 'may cost lives,' doctors say

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

The high cost of giving birth even with insurance

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

In age of alternative facts, a scholarly course on calling out crap

'Null' research findings aren't empty of meaning. Let's publish them

knowledge

Group behind ProMed defends move to subscription

Why do we get seasonal allergies?

UnitedHealth wins $3.3 billion takeover of Amedisys

The a glaring gap in research on serious mental illness and primary care

FDA scientists endorse Pfizer/BioNTech Covid

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

entertainment

knowledge

focus

focus